Recent studies have shown that dagliflozin attenuates angiotensin II infusion-induced cardiac hypertrophy, fibrosis and increased collagen synthesis by inhibiting the TGF-β1/Smads signaling pathway [56]. This evidence concerns the gene AGT and cardiac hypertrophy.